ADARx Pharmaceuticals (NASDAQ:ADRX) Stock: Insider Orbimed Advisors Llc Acquires 950,000 Shares

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Orbimed Advisors Llc bought 950,000 shares of the business’s stock in a transaction dated Monday, September 28th. The shares were acquired at an average cost of $17.00 per share, with a total value of $16,150,000.00. Following the completion of the purchase, the director owned 14,325,529 shares in the company, valued at approximately $243,533,993. This represents a 7.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ADARx Pharmaceuticals Stock Performance

Shares of ADARx Pharmaceuticals stock traded down $0.70 during trading on Wednesday, reaching $19.94. The company’s stock had a trading volume of 788,778 shares, compared to its average volume of 1,097,539. ADARx Pharmaceuticals, Inc. has a 12-month low of $18.50 and a 12-month high of $23.21.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.